文献速递治疗药物监测与药物基因组学

靶部位药物暴露群体药代动力学建模方法综述

Methodologies for Population Pharmacokinetic Modeling of Target-Site Drug Exposure: A Narrative Review of Current Strategies.
PubMed 文献 · Clin Pharmacokinet · 2026-02-08

该叙述性综述梳理了文献中描述血浆与靶部位药物浓度关系的四种群体药代动力学建模策略,包括流入流出速率常数模型、室间清除率模型、效应室模型及将靶部位纳入中央或外周室的模型,并讨论基于靶部位浓度进行治疗药物监测的可行性与局限,指出靶部位浓度已在特定临床场景中显示优化治疗的潜力。

要点

  • 四种建模策略可刻画血浆与靶部位浓度关系,支持模型引导精准给药。
  • 基于靶部位浓度的TDM受侵入性采样、样本量有限及缺乏既定PK/PD靶值限制。
  • 即使靶部位暴露差异较小也可能有临床意义,危重症患者中已有应用证据。

核心结论

  • 靶部位浓度已可通过不同建模方法成功预测,并在部分临床病例中显示优化治疗的潜力。

研究设计与样本

  • 叙述性综述,汇总文献中描述血浆与靶部位药物浓度关系的群体药代动力学建模策略。

主要发现

  • 文献描述了四种建模策略:流入流出速率常数、室间清除率、效应室模型及靶部位纳入中央或外周室。
  • 流入流出速率常数模型尤其适用于单向转运或流量差异较大的情形。
  • 室间清除率模型以单一参数捕捉双向转运,该参数可直接与消除清除率或血流量比较。
  • 效应室模型用于描述组织分布延迟。
  • 基于靶部位浓度的治疗药物监测实施受侵入性采样、样本量有限及缺乏既定PK/PD靶值限制。

临床怎么用

  • 选择建模策略时应考虑转运方向、流量差异及组织分布延迟等特征。
  • 在危重症患者等特定场景可考虑基于靶部位浓度进行药物监测以优化治疗。

局限性

  • 基于靶部位浓度的治疗药物监测受侵入性采样程序限制。
  • 靶部位采样样本量有限。
  • 缺乏既定的药代动力学/药效动力学靶值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Model-informed precision dosing (MIPD) is increasingly used to guide drug dosing based on population pharmacokinetic (popPK) models developed mainly using plasma concentration data. However, plasma levels may not always correlate well with drug concentrations at the site of action, potentially leading to under- or overestimation of target-site exposure. It is, therefore, important to evaluate which popPK modeling approaches effectively describe drug concentrations at target sites other than plasma to support the selection and implementation of appropriate modeling techniques. This review outlines four general modeling strategies described in literature characterizing the relationship between plasma and target-site drug concentrations. The first approach includes rate constants describing inflow and outflow, which is especially useful for unidirectional transport or large flow rate differences. Second, intercompartmental clearance models capture bidirectional transport with a single parameter that is directly comparable with elimination clearance or blood flow. Third, effect compartment models are used to describe delayed tissue distribution. Lastly, the target site can be modeled as part of either the central or the peripheral compartment. Although therapeutic drug monitoring (TDM) based on target-site concentrations has been suggested, implementation is limited by invasive sampling procedures, limited sample volumes, and the lack of established pharmacokinetic/pharmacodynamic targets. Nevertheless, even small differences in target-site exposure can result in clinical implications, and the applicability of drug monitoring using target-site concentrations has been shown in critically ill patients. In conclusion, target-site concentrations have been successfully predicted using different modeling methodologies and have demonstrated potential to optimize therapy in select clinical cases.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Mehciz M, Rietveld PCS, Koch BCP, et al. Methodologies for Population Pharmacokinetic Modeling of Target-Site Drug Exposure: A Narrative Review of Current Strategies. Clin Pharmacokinet. 2026. PMID: 41656453. doi:10.1007/s40262-026-01620-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。